One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow.

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow. This is shown in a study by the University of Gothenburg, Sweden.

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.